On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection

(2020) Ana Pertejo-Fernandez et al.   LUNG CANCER

Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer

(2020) Dan Pu et al.   MEDICINE

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events

(2020) Junling Zhuang et al.   Thoracic Cancer

Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection

(2020) Ruben C. Hoogeveen et al.   Frontiers in Immunology

Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019

(2020) Yuan-Yuan Qin et al.   CHINESE MEDICAL JOURNAL

COVID-19: the use of immunotherapy in metastatic lung cancer

(2020) Alexander P Davis et al.   Immunotherapy

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

(2020) Melissa Bersanelli   Immunotherapy

Risk-adapted Treatment Strategy For COVID-19 Patients

(2020) Changcheng Zheng et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy

(2020) Angela Ceribelli et al.   JOURNAL OF AUTOIMMUNITY

The many faces of the anti-COVID immune response

(2020) Santosha A. Vardhana et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Metastatic melanoma treatment with check point inhibitors in the COVID‐19 era: experience from an Italian Skin Cancer Unit

(2020) Pietro Quaglino et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study

(2020) Chai Yeong Hong et al.   JOURNAL OF VIRAL HEPATITIS

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers

(2020) Jia Luo et al.   Cancer Discovery

Covid-19: risk factors for severe disease and death

(2020) Rachel E Jordan et al.   BMJ-British Medical Journal

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

(2020) Bo Diao et al.   Frontiers in Immunology

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

(2020) Paolo Antonio Ascierto et al.   Journal for ImmunoTherapy of Cancer

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

(2020) Raju K. Vaddepally et al.   Cancers

The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence

(2020) G. Tapia Rico et al.   CANCER TREATMENT REVIEWS

What the oncologist needs to know about COVID-19 infection in cancer patients

(2020) Elie Rassy et al.   Future Oncology

A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab

(2020) Lucia Bonomi et al.   Journal of Thoracic Oncology

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors

(2019) Magid Awadalla et al.   Journal for ImmunoTherapy of Cancer

Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer

(2019) Michael R. Cook et al.   JAMA Oncology

Progressive multifocal leukoencephalopathy treated with nivolumab

(2019) Ethan Hoang et al.   JOURNAL OF NEUROVIROLOGY

Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors (ICI)

(2019) Curtis R Chong et al.   CLINICAL INFECTIOUS DISEASES

Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action

(2019) Ni Zhang et al.   Immunotherapy

Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

(2019) Irene Cortese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Can Immune Checkpoint Inhibitors Keep JC Virus in Check?

(2019) Igor J. Koralnik   NEW ENGLAND JOURNAL OF MEDICINE

Immune related adverse events in cancer patients receiving influenza vaccination and immune checkpoint inhibitors

(2019) Geert H Groeneveld et al.   CLINICAL INFECTIOUS DISEASES

State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough

(2019) Melissa Bersanelli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study

(2019) Edward Gane et al.   JOURNAL OF HEPATOLOGY

Workup and Management of Immune‐Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment

(2019) Christine Hsu et al.   ONCOLOGIST

Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors

(2019) Morgan E Gwynn et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Sustained Response and Rationale of Programmed Cell Death-1-Targeting for Progressive Multifocal Leukoencephalopathy

(2019) Alexandra Audemard-Verger et al.   Open Forum Infectious Diseases

CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy

(2019) Zhengming Xiong et al.   CLINICAL CANCER RESEARCH

Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor

(2019) Bhumsuk Keam et al.   CLINICAL INFECTIOUS DISEASES

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

(2019) Neil J. Shah et al.   Journal for ImmunoTherapy of Cancer

Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency

(2018) Vanessa A. Evans et al.   AIDS

CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions

(2018) Masao Hashimoto et al.   Annual Review of Medicine

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)

(2018) G. Redelman-Sidi et al.   CLINICAL MICROBIOLOGY AND INFECTION

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

(2018) Elizabeth Colston et al.   PLoS One

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

(2018) Heinz Läubli et al.   Journal for ImmunoTherapy of Cancer

AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL).

(2018) Lakshmi Rajdev et al.   JOURNAL OF CLINICAL ONCOLOGY

Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors

(2018) Karthik Suresh et al.   Journal of Thoracic Oncology

Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells

(2018) Cherry S. Leung et al.   Genome Medicine

Influenza vaccination in patients with lung cancer receiving anti–programmed death receptor 1 immunotherapy does not induce immune-related adverse events

(2018) Dirk H. Wijn et al.   EUROPEAN JOURNAL OF CANCER

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

(2018) Melissa Bersanelli et al.   Immunotherapy

Role of cytokine agonists and immune checkpoint inhibitors toward HIV remission

(2018) Timothy N. Hoang et al.   Current Opinion in HIV and AIDS

The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection—A Mini Comment on the 2018 Medicine Nobel Prize

(2018) Jia Liu et al.   VIROLOGICA SINICA

Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm

(2017) Martin Rao et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV Working Group

(2017) Thomas S. Uldrick et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

(2017) Cynthia L. Gay et al.   JOURNAL OF INFECTIOUS DISEASES

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Severe cytokine release syndrome in a patient receiving PD-1-directed therapy

(2017) Seth J. Rotz et al.   PEDIATRIC BLOOD & CANCER

Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway

(2016) Yong Yu et al.   NATURE

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

(2016) K. E. Pauken et al.   SCIENCE

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus

(2016) Anurodh Shankar Agrawal et al.   Human Vaccines & Immunotherapeutics

Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection

(2016) Matthias Hoffmann et al.   PLoS Pathogens

Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options

(2015) Vijayakumar Velu et al.   Retrovirology

PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination

(2014) A. C. Finnefrock et al.   JOURNAL OF IMMUNOLOGY

Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection

(2014) Jia Liu et al.   PLoS Pathogens

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection

(2013) David Gardiner et al.   PLoS One

Increased Program Cell Death–1 Expression on T Lymphocytes of Patients With Progressive Multifocal Leukoencephalopathy

(2012) Chen Sabrina Tan et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

CD200 Receptor Controls Sex-Specific TLR7 Responses to Viral Infection

(2012) Guruswamy Karnam et al.   PLoS Pathogens

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

(2010) Chen S Tan et al.   LANCET NEUROLOGY

Coexpression of PD-1, 2B4, CD160 and KLRG1 on Exhausted HCV-Specific CD8+ T Cells Is Linked to Antigen Recognition and T Cell Differentiation

(2010) Bertram Bengsch et al.   PLoS Pathogens

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE